The 8p11 myeloproliferative syndrome (EMS) also known as stem cell leukemia-lymphoma syndrome (SCLL) is associated with translocations that disrupt FGFR1. The resultant fusion proteins are constitutively active tyrosine kinases, and different FGFR1 fusions are associated with subtly different disease phenotypes. We report here a patient with a t(8;17)(p11;q23) and an unusual myelodysplastic/myeloproliferative disease (MDS/MPD) characterized by thrombocytopenia due to markedly reduced size and numbers of megakaryocytes, with elevated numbers of monocytes, eosinophils and basophils. A novel mRNA fusion between exon 32 of the myosin XVIIIA gene (MYO18A) at chromosome band 17q11 and exon 9 of FGFR1 was identified. Partial characterization of the genomic breakpoints in combination of bubble-PCR with fluoresence in situ hybridization revealed that the t(8;17) arose from a threeway translocation with breaks at 8p11, 17q11 and 17q23. MYO18A-FGFR1 is structurally similar to other fusion tyrosine kinases and is likely to be the causative transforming lesion in this unusual MDS/MPD.
Introduction
A minority of patients with clinical and hematological features that are suggestive of chronic myelogenous leukemia (CML) lack the Philadelphia-chromosome (Ph) and/or the BCR-ABL fusion gene. In the absence of other known genetic defects patients are usually referred to as atypical CML (aCML), or more broadly unclassifiable myeloproliferative or myelodysplastic/myeloproliferative disease (MDS/MPD) according to the World Health Organization (WHO) classification. 1 Typical features at presentation in addition to the common leukocytosis are a marked granulocytic and often multilineage dysplasia, which are usually not observed in BCR-ABL positive CML. Owing to the presence of elevated monocytes in a significant proportion of patients, a considerable overlap exists between aCML and chronic myelomonocytic leukemia (CMML).
A small proportion of patients diagnosed with aCML, CMML or unclassified MPD or MDS/MPD have been characterized recently by the presence of fusion genes in which unrelated partner genes are fused to other tyrosine kinases, for example, fibroblast growth factor receptor 1 (FGFR1), platelet derived growth factor receptor A (PDGFRA) and PDGFRB. [2] [3] [4] A characteristic feature in the majority of these patients is an additional marked eosinophilia, which leads as the prominent feature in rare cases to the diagnosis of chronic eosinophilic leukaemia (CEL).
Here we describe the identification of a novel MYO18A-FGFR1 fusion as a consequence of a t(8;17) in a patient with an unusual MDS/MPD phenotype characterized by a massive leftshifted dysplastic leucocytosis with elevated monocytes, eosinophils and basophils plus thrombocytopenia due to decreased and dysplastic megakaryoctes.
Materials and methods

Case report
A 74-year-old female with a 2 years history of a CML-like myeloproliferative syndrome was referred with fever, night sweats and weight loss of 5 kg within 3 months. The spleen was not enlarged. Sequential peripheral blood counts revealed leukocytosis between 80 Â 10 9 /l and 110 Â 10 9 /l with a CMLlike left shift, pronounced monocytes (17-25%), eosinophils (3-8%) and basophils (4-8%) plus marked thrombocytopenia between 8 Â 10 9 /l and 15 Â 10 9 /l ( Figure 1a ). The bone marrow was hypercellular (3 þ CALGB) with marked and slightly dysplastic granulopoiesis plus pronounced monocytes (20%), eosinophils (5%) and basophils (4%). Numbers of blasts were slightly increased (4%). Megakaryocytes were extremely rare but occasional micromegakaryocytes were present (Figure 1b) . Cytogenetic analysis showed 47,XX,t(8;17)(p11;q23), þ 20 [15] . The additional chromosome 20 was confirmed by interphase-FISH and multicolor FISH analysis. The patient was treated for the first 2 years with standard-dose busulfan intermittently. After a rapid increase of leukocytes, treatment was switched to hydroxycarbamide. No hematological response was achieved and low-dose cytarabine was therefore added by intermittent subcutaneous administration. The patient remained in a stable clinical condition but did not achieve a partial or complete hematological response. Although idarubicin was added, the patient died due to treatment-resistant disease progression and concomitant infection soon after. Mannheim, Germany). Briefly, 1 mg RNA extracted from peripheral blood leukocytes using the RNeasy system (Qiagen, Hilden, Germany) was reverse transcribed using primer F12-: 5 0 -GGAGGCATACTCCACGATGACA-3 0 . Nested PCR was performed with primer F10-: 5 0 -TCTTCACAGCCACTTTGGTCACA -3 0 in the first step and primer F9-: 5 0 -AGAAGAACCCCAG AGTTCATGGA-3 0 in the second step in conjunction with RACE anchor primers supplied by the manufacturer. Products were cloned using the TOPO cloning kit (Invitrogen, Leek, The Netherlands) and sequenced.
RACE-PCR
RT-PCR
RNA was reverse transcribed with random hexamers using standard techniques. 5 Primers used to detect MYO18A-FGFR1 cDNA were MYO þ : 5 0 -AAGGAGATGGAGAGTCGGGATG-3 0 and F9À: 5 0 -AGAAGAACCCCAGAGTTCATGGA-3 0 . Reciprocal FGFR1-MYO18A fusion transcripts were checked for using primers F7 þ : 5 0 -TGGTACCAAGAAGAGTGACTTCCA-3 0 and MYOÀ: 5 0 -TGCAGGTGCAGGTCTTCGATCT-3 0 . All amplifications were performed for 32 cycles at 601C annealing.
Genomic PCR
Primers derived from sequences flanking the putative genomic breakpoints within MYO18A and FGFR1 were used in various combinations to amplify the forward and reciprocal junctions by long-template PCR (LT-PCR) following the manufacturers instructions (Roche Diagnostics). Bubble-PCR to amplify genomic junction fragments was carried out essentially as described using MYO18A, FGFR1 and bubble-specific primers. 6 Rearranged bands were sequenced either directly or after cloning using the TOPO cloning kit (Invitrogen). The sequences of the primers are available on request.
Fluorescence in situ hybridization (FISH)
RPCI-1 library PAC clones for the regions 5 0 and 3 0 FGFR1 (dJ162N14 and dJ224C10) have been described previously. 7 BAC clones 5 0 and 3 0 MYO18A (RP11-22N12 and RP11-20B24), centromeric and telomeric 17q23 (RP11-13J7 and RP11-95K18) were identified from www.ensembl.org or http://genome. ucsc.edu and obtained from the Sanger Institute (Cambridge, UK). FISH was performed according to standard procedures.
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Results
To our knowledge, the t(8;17)(p11;q23) has not been described previously. Although the precise clinical phenotype of the patient described above was unusual, the combination of MPD, eosinophilia and rearrangement of 8p11 suggested FGFR1 may normal 17
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C Walz et al be involved. As all known fusions in EMS involve FGFR1 exon 9 at the mRNA junction, 5 0 -RACE-PCR was employed. The resulting PCR products consisted of sequences derived from a known gene, MYO18A (MYO18A: REFSEQ:NM_203318), fused to FGFR1. Chimeric MYO18A-FGFR1 transcripts were confirmed by RT-PCR and indicated an in-frame fusion of MYO18A exon 32 to FGFR1 exon 9 (Figure 2a,b) . Reciprocal FGFR1-MYO18A transcripts were not detected. MYO18A-FGFR1 is predicted to encode a protein of 2085 amino acids consisting of more than 80% of MYO18A (1691 amino acids) plus the entire tyrosine kinase domain and part of the juxtamembrane region from FGFR1 (394 amino acids).
MYO18A is located at 17q11, whereas the breakpoint had been assigned cytogenetically to 17q23. To clarify the reasons for this we determined the genomic breakpoints. Using LT-PCR and forward and reverse primers designed from MYO18A intron 32 and FGFR1 intron 8 we were able to amplify the MYO18A-FGFR1 genomic junction sequences, but not the reciprocal product. The absence of a reciprocal genomic product suggested that a deletion or complex rearrangement might have taken place. We therefore used a one-sided amplification technique, bubble PCR, to try and isolate sequences that were fused to the 5 0 portion of FGFR1 and 3 0 portion of MYO18A. We found that the proximal end of FGFR1 intron 8 sequence was fused to a sequence derived from 17q23.2, but we were unable to identify any extraneous sequence fused to the 3 0 end of MYO18A (Figure 2c) .
We used FISH to further clarify the nature of the rearrangement. FISH with BAC clones 5 0 to MYO18A and 3 0 to FGFR1 showed a fusion on the derivative chromosome 17 (Figure 1c) , is oriented from centromere to telomere, whereas MYO18A at 17q11 is oriented from telomere to centromere. A three-way translocation took place, resulting in the MYO18A-FGFR1 fusion on the der(17), plus inversion of 17q11-17q23. The der(8) breakpoint joins the 5 0 part of FGFR1 to 17q23.
MYO18A-FGFR1
signal (not shown). FISH with flanking BACs showed a split signal for FGFR1 but no split for MYO18A (Figure  1d ,e), indicating that both 5 0 and 3 0 MYO18A were retained on chromosome 17. BACs flanking the 17q23 sequence obtained by bubble-PCR showed translocation of the telomeric sequence to the derivative chromosome 8 while the centromeric BAC was retained on the derivative chromosome 17 (Figure 1f) . In confirmation of the bubble-PCR results, FISH with 5 0 FGFR1 colocalized with the telomeric 17q23 BAC (not shown). These results suggest that regions distal to 8p11 and 17q23 were translocated to the reciprocal derivative chromosomes, while an inversion occurred of the chromosome 17q region between 17q11 and 17q23 bringing together 5 0 MYO18A and 3 0 FGFR1 on the derivative chromosome 17 (Figure 2d ). This complex rearrangement may have mimicked a t(8;17)(p11;q23).
Discussion
An increasing number of tyrosine kinase fusion genes that result from chromosomal translocations or deletions have been described in MPD and MDS/MPD. Although eosinophilia is present in the vast majority of these patients, the different tyrosine kinases and even different fusion genes of the same tyrosine kinase are associated with subtly different morphological phenotypes and highly variable clinical courses. For example, six distinct fusions involving FGFR1 have been identified in association with the 8p11 myeloproliferative syndrome (EMS), 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] also known as stem cell leukemialymphoma syndrome (SCLL). The partner genes (ZNF198, FOP, CEP110, BCR, HERV-K and FGFR1OP2) are believed to promote dimerization and ligand-independent activation of the FGFR1 tyrosine kinase, deregulating hematopoiesis in a manner analogous to BCR-ABL. 4 The different FGFR1 fusions are associated with subtly different disease phenotypes, although the number of cases reported with each abnormality are small. 2 For example, the t(8;22) is associated with a clinical and hematological picture very similar to that seen in BCR-ABL positive CML, whereas thrombocytopenia and monocytosis resembling CMML are more frequently present in cases with a t(6;8) or t(8;9). Strikingly, most patients with the t(8;13) present with or develop T-cell non-Hodgkin's lymphoma (T-NHL) in addition to having a myeloproliferative disorder (MPD). In our patient the peripheral blood smear was suggestive of a MDS/MPD phenotype. In favor of a CML-like disease were the marked leukocytosis with a typical left shift and the pronounced basophils, whereas granulocytic dysplasia, monocytosis and the persistent thrombocytopenia resembled MDS. Surprisingly, thrombocytopenia was due to a dramatic decrease of dysplastic megakaryocytes. They were completely absent in Giemsastained cytology, whereas histopathology revealed at least occasional micromegakaryocytes.
We determined that the t(8;17) was a complex rearrangement at the molecular level, although cytogenetically it appeared as a simple reciprocal exchange. FGFR1 and MYO18A are in opposite orientations with respect to the centromere (http:// genome.ucsc.edu/ May 2004 hg17 assembly), and therefore a simple reciprocal exchange and in frame fusion of these two genes would result in acentric and dicentric derivatives that could not segregate correctly at mitosis. An inversion is necessary to produce derivative chromosomes each with one centromere. Similar findings have been described for other rare translocations and probably explain, at least in part, why these rearrangements are so uncommon.
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MYO18A is a member of the myosin superfamily (myosin 18A) that was originally identified in hemopoietic supportive bone marrow stromal lines and which is expressed as multiple isoforms. [18] [19] [20] Although the function of MYO18A is not understood, one isoform is tyrosine phosphorylated after colonystimulating factor-1 receptor signaling. 20 MYO18A is widely expressed and contains several functional motifs that are retained in MYO18A-FGFR1, including an N-terminal PDZ (PSD-95/Dlg/ZO-1) protein-protein interaction domain, a myosin head domain and a region that is predicted to form multiple coiled-coils. As has been found for other tyrosine kinase fusion proteins it is likely that one or more of these motifs result in dimerization or oligomerization of MYO18A-FGFR1, with consequent constitutive activation of the FGFR1 kinase domain. 4, 21 In summary, we have identified a novel MYO18A-FGFR1 fusion in a patient with atypical MDS/MPD. This finding further supports a prominent role for FGFR1 in the pathogenesis of these diseases and the prospect for more accurate diagnosis and, potentially, targeted therapy. 7, 22, 23 
